The beat on Q1 adjusted EPS and raised full-year guidance signal continued momentum in core therapeutic areas. Watch for FDA decisions on Skyrizi SC induction for Crohn's disease and Rinvoq for alopecia areata, which could further drive upside. Monitor Humira erosion trajectory and regulatory developments on trenibotulinumtoxinE.
ABBV drugs
ABBV drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 29 $203.89entry
- T+1 · 7mo ago +3.64%α +2.62% · $211.32
- T+5 · 7mo ago +1.09%α −2.02% · $206.11
- T+20 · 6mo ago +5.65%α +0.19% · $215.40
- T+60 · 4mo ago +27.21%α +23.09% · $259.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AbbVie reported Q1 2026 adjusted EPS of $2.65, above the prior company guidance range of $2.56-$2.60, and revenue of $15.002B (+12.4% YoY). The company raised full-year 2026 adjusted EPS guidance from $13.96-$14.16 to $14.08-$14.28, driven by strong growth in immunology (Skyrizi +30.9%, Rinvoq +23.3%) and neuroscience (+26.0%).
Key Financial Metrics
Key Facts
- Q1 2026 net revenue $15.002B, +12.4% YoY reported, +10.3% operational
- Q1 2026 adjusted diluted EPS $2.65, +7.7% YoY; GAAP EPS $0.39, -45.8% YoY
- Full-year 2026 adjusted diluted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16
- Immunology revenue $7.290B (+16.4%), neuroscience $2.875B (+26.0%)
- Acquired IPR&D and milestones expense of $744M pre-tax ($0.41 per share drag)
Financial Impact
Revenue grew 12.4% to $15.002B, adjusted EPS up 7.7% to $2.65, full-year guidance raised by $0.12 at midpoint.
Risk Factors
- Humira revenue declining 38.6% YoY; Imbruvica down 24.7%
- FDA Complete Response Letter for trenibotulinumtoxinE (manufacturing issues)
- Reliance on Skyrizi and Rinvoq for growth; competition from biosimilars and new entrants
- Large non-cash charges (contingent consideration, amortization) depress GAAP earnings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001551152-26-000013 |
| Document: abbv-20260429.htm | 0001551152-26-000013 |
| Document: 0001551152-26-000013-index-headers.html | 0001551152-26-000013 |
| Document: 0001551152-26-000013-index.html | 0001551152-26-000013 |
| Document: 0001551152-26-000013.txt | 0001551152-26-000013 |
| 8-K Data (Synthetic) | 0001551152-26-000013 |
Track record
22 reports on ABBV
6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +24.02% at T+60 after the Apr 21, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
- Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
- Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
- Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers